中国循证心血管医学杂志
中國循證心血管醫學雜誌
중국순증심혈관의학잡지
CHINESE JOURNAL OF EVIDENCE-BASES CARDIOVASCULAR MEDICINE
2014年
6期
653-657
,共5页
吴平勇%曾宪涛%王学军%张超%肖敏%陈立东%张绪国
吳平勇%曾憲濤%王學軍%張超%肖敏%陳立東%張緒國
오평용%증헌도%왕학군%장초%초민%진립동%장서국
川芎嗪%心肌缺血再灌注损伤%系统评价%Meta分析
川芎嗪%心肌缺血再灌註損傷%繫統評價%Meta分析
천궁진%심기결혈재관주손상%계통평개%Meta분석
Ligustrazine%Myocardial ischemia-reperfusion injury%Systematic review%Meta-analysis
目的:系统评价川芎嗪对心肌缺血再灌注损伤防治作用的疗效和安全性。方法计算机检索CBM、CNKI、维普数据库和谷歌学术搜索,收集川芎嗪对心肌缺血再灌注防治作用的随机对照试验(RCT),检索时限均为建库至2014年1月。由两名研究者按照纳入与排除标准独立筛选文献、提取资料和评价质量后,采用RevMan 5.2软件进行Meta分析。结果最终纳入23个RCT共1984例患者。Meta分析结果显示:川芎嗪组对心肌缺血再灌注损伤所致临床症状改善明显优于对照组3.01倍(OR=3.01,95%CI:2.35~3.86)。有5个RCT报道了川芎嗪组发生了不良事件,主要是腹胀、恶心、凝血时间延长等,12个RCT明确提及无严重不良事件发生,6个RCT未报道药物不良反应的相关信息。结论基于当前证据,川芎嗪具有防治心肌缺血再灌注损伤作用,且严重不良反应少。受纳入研究质量与数量限制,上述结果尚待更多和更高质量研究进一步证实。
目的:繫統評價川芎嗪對心肌缺血再灌註損傷防治作用的療效和安全性。方法計算機檢索CBM、CNKI、維普數據庫和穀歌學術搜索,收集川芎嗪對心肌缺血再灌註防治作用的隨機對照試驗(RCT),檢索時限均為建庫至2014年1月。由兩名研究者按照納入與排除標準獨立篩選文獻、提取資料和評價質量後,採用RevMan 5.2軟件進行Meta分析。結果最終納入23箇RCT共1984例患者。Meta分析結果顯示:川芎嗪組對心肌缺血再灌註損傷所緻臨床癥狀改善明顯優于對照組3.01倍(OR=3.01,95%CI:2.35~3.86)。有5箇RCT報道瞭川芎嗪組髮生瞭不良事件,主要是腹脹、噁心、凝血時間延長等,12箇RCT明確提及無嚴重不良事件髮生,6箇RCT未報道藥物不良反應的相關信息。結論基于噹前證據,川芎嗪具有防治心肌缺血再灌註損傷作用,且嚴重不良反應少。受納入研究質量與數量限製,上述結果尚待更多和更高質量研究進一步證實。
목적:계통평개천궁진대심기결혈재관주손상방치작용적료효화안전성。방법계산궤검색CBM、CNKI、유보수거고화곡가학술수색,수집천궁진대심기결혈재관주방치작용적수궤대조시험(RCT),검색시한균위건고지2014년1월。유량명연구자안조납입여배제표준독립사선문헌、제취자료화평개질량후,채용RevMan 5.2연건진행Meta분석。결과최종납입23개RCT공1984례환자。Meta분석결과현시:천궁진조대심기결혈재관주손상소치림상증상개선명현우우대조조3.01배(OR=3.01,95%CI:2.35~3.86)。유5개RCT보도료천궁진조발생료불량사건,주요시복창、악심、응혈시간연장등,12개RCT명학제급무엄중불량사건발생,6개RCT미보도약물불량반응적상관신식。결론기우당전증거,천궁진구유방치심기결혈재관주손상작용,차엄중불량반응소。수납입연구질량여수량한제,상술결과상대경다화경고질량연구진일보증실。
Objective To review systematically the preventive and therapeutic effects of ligustrazine on myocardial ischemia-reperfusion injury.Methods The databases of CBM, CNKI, VIP Database and Google Scholar were retrieved for collecting the randomized controlled trials (RCT) about the preventive and therapeutic effects of ligustrazine on myocardial ischemia-reperfusion injury from database establishment time to Jan. 2014. The data was screened according to inclusion and exclusion criteria, extracted and given quality reviewe by 2 researchers independently, and then given Meta-analysis by applying RevMan 5.2 software.Results There were totally 23 RCT included involving 1984 cases, and the results of Meta-analysis showed that the relieving rate of clinical symptoms was increased by 3.01 times in ligustrazine group than that in control group [OR=3.01, 95%CI=(2.35-3.86)]. In ligustrazine group, 5 RCT reported adverse events including mainly abdorminal distention, nausea and prolonged thrombin time, 12 RCT denied serious adverse events, and 6 RCT did not report drug adverse reactions.Conclusion Based on present evidence, ligustrazine has preventive and therapeutic effects on myocardial ischemia-reperfusion injury. As this analysis has limited quantity and quality, more large-sample RCT with higher quality are required for further identifying the results.